Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Incyte announced FDA approval of Jakafi XR, a once-daily extended-release formulation of ruxolitinib, for myelofibrosis, polycythemia vera, and graft-versus-host disease. The approval is supported by clinical data showing that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to the standard 25 mg twice-daily dosage.
Key figures
- Drug Name
- Jakafi XR (ruxolitinib)
- Bioequivalence
- 55 mg Jakafi XR QD bioequivalent to 25 mg Jakafi BID
- Availability Date
- May 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.